9OF Stock Overview
Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BioRestorative Therapies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.16 |
| 52 Week High | US$2.22 |
| 52 Week Low | US$0.76 |
| Beta | 61.98 |
| 1 Month Change | 54.29% |
| 3 Month Change | 58.82% |
| 1 Year Change | 56.52% |
| 3 Year Change | -36.47% |
| 5 Year Change | n/a |
| Change since IPO | -65.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9OF | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 9.6% | -0.9% | 0.3% |
| 1Y | 56.5% | -6.0% | 12.9% |
Return vs Industry: 9OF exceeded the German Biotechs industry which returned -6% over the past year.
Return vs Market: 9OF exceeded the German Market which returned 12.9% over the past year.
Price Volatility
| 9OF volatility | |
|---|---|
| 9OF Average Weekly Movement | 15.4% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9OF's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9OF's weekly volatility has decreased from 21% to 15% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 11 | Lance Alstodt | www.biorestorative.com |
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue.
BioRestorative Therapies, Inc. Fundamentals Summary
| 9OF fundamental statistics | |
|---|---|
| Market cap | €15.83m |
| Earnings (TTM) | -€9.27m |
| Revenue (TTM) | €362.30k |
43.5x
P/S Ratio-1.7x
P/E RatioIs 9OF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9OF income statement (TTM) | |
|---|---|
| Revenue | US$377.00k |
| Cost of Revenue | US$24.73k |
| Gross Profit | US$352.27k |
| Other Expenses | US$10.00m |
| Earnings | -US$9.65m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.39 |
| Gross Margin | 93.44% |
| Net Profit Margin | -2,558.95% |
| Debt/Equity Ratio | 0% |
How did 9OF perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/05 03:32 |
| End of Day Share Price | 2025/02/05 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioRestorative Therapies, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Okunewitch | Maxim Group |
| Elemer Piros | Roth Capital Partners |
| Jonathan Aschoff | Roth Capital Partners |